Opus Genetics Inc (IRD)

$5.23 +0.02 (0.38%)
Market Cap 372.00M
Revenue (ttm) 14.20M
Net Income (ttm) -49.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -349.23%
Debt to Equity Ratio 0.00
Volume 655,400
Avg Vol 867,214
Day's Range N/A - N/A
Shares Out 71.40M
Stochastic %K 33%
Beta 0.52
Analysts Strong Sell
Price Target $9.93

Company Profile

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
TruthTooPower
TruthTooPower Apr. 24 at 5:21 PM
$IRD!!! Oh Hell Yeah!!! 🙌🙌🙌
0 · Reply
TruthTooPower
TruthTooPower Apr. 24 at 2:57 PM
$IRD!!! Add All Day!!! Thank Me Later!!!
0 · Reply
RayRayStocks
RayRayStocks Apr. 24 at 2:21 PM
$IRD 5 year cup with handle forming
0 · Reply
History101
History101 Apr. 23 at 9:00 PM
$IRD 478 watching 4/23/2026
0 · Reply
History101
History101 Apr. 23 at 8:59 PM
$IRD damn, someone wanted a LOT of shares at close...bullish
0 · Reply
TheAliAbdul
TheAliAbdul Apr. 23 at 3:23 PM
$IRD stay above $5.00 and we are still bullish
0 · Reply
WickFinder
WickFinder Apr. 22 at 4:07 PM
$IRD quiet name no real pressure but also no buyers yet
1 · Reply
dick_dasterdly
dick_dasterdly Apr. 22 at 10:32 AM
$IRD We just never collapse here. Any news whatsoever and..
0 · Reply
TruthTooPower
TruthTooPower Apr. 20 at 4:30 PM
$IRD!!! NAZ is down!!! Adding on Down Days Looking for my DOUBLE DIGITS!!!
0 · Reply
Shivan007
Shivan007 Apr. 20 at 2:02 PM
$IRD why is it falling? Is there any news?
1 · Reply
Latest News on IRD
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Apr 10, 2026, 6:59 AM EDT - 15 days ago

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Apr 6, 2026, 7:00 AM EDT - 19 days ago

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Mar 24, 2026, 7:00 AM EDT - 4 weeks ago

Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Mar 10, 2026, 7:00 AM EDT - 6 weeks ago

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Mar 3, 2026, 8:00 AM EST - 7 weeks ago

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Feb 27, 2026, 10:10 AM EST - 2 months ago

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Feb 25, 2026, 6:59 AM EST - 2 months ago

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Announces $25 Million Private Placement

Feb 13, 2026, 7:30 AM EST - 2 months ago

Opus Genetics Announces $25 Million Private Placement

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Feb 2, 2026, 8:00 AM EST - 2 months ago

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Jan 27, 2026, 7:00 AM EST - 3 months ago

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Jan 8, 2026, 7:00 AM EST - 3 months ago

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 16, 2025, 4:01 PM EST - 4 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 4 months ago

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Dec 9, 2025, 7:00 AM EST - 4 months ago

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Opus Genetics to Participate in Upcoming Investment Conferences

Nov 20, 2025, 8:00 AM EST - 5 months ago

Opus Genetics to Participate in Upcoming Investment Conferences

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Nov 13, 2025, 7:00 AM EST - 5 months ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 5 months ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces $23 Million Registered Direct Offering

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Nov 6, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 14, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Oct 2, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Sep 30, 2025, 7:00 AM EDT - 7 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Sep 2, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 27, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 18, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 9 months ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 5, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 23, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 4:30 PM EDT - 10 months ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 26, 2025, 6:55 AM EDT - 10 months ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Jun 23, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 11, 2025, 3:47 PM EDT - 1 year ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics to Participate in Upcoming Investor Conference in April

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Mar 31, 2025, 8:20 AM EDT - 1 year ago

Opus Genetics Announces Financial Results for Full Year 2024

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 5:03 PM EDT - 1 year ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:30 AM EDT - 1 year ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 21, 2025, 9:11 AM EDT - 1 year ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 5, 2025, 8:00 AM EST - 1 year ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 26, 2025, 8:00 AM EST - 1 year ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 18, 2025, 7:30 AM EST - 1 year ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Feb 7, 2025, 9:15 AM EST - 1 year ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Dec 19, 2024, 8:00 AM EST - 1 year ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

TruthTooPower
TruthTooPower Apr. 24 at 5:21 PM
$IRD!!! Oh Hell Yeah!!! 🙌🙌🙌
0 · Reply
TruthTooPower
TruthTooPower Apr. 24 at 2:57 PM
$IRD!!! Add All Day!!! Thank Me Later!!!
0 · Reply
RayRayStocks
RayRayStocks Apr. 24 at 2:21 PM
$IRD 5 year cup with handle forming
0 · Reply
History101
History101 Apr. 23 at 9:00 PM
$IRD 478 watching 4/23/2026
0 · Reply
History101
History101 Apr. 23 at 8:59 PM
$IRD damn, someone wanted a LOT of shares at close...bullish
0 · Reply
TheAliAbdul
TheAliAbdul Apr. 23 at 3:23 PM
$IRD stay above $5.00 and we are still bullish
0 · Reply
WickFinder
WickFinder Apr. 22 at 4:07 PM
$IRD quiet name no real pressure but also no buyers yet
1 · Reply
dick_dasterdly
dick_dasterdly Apr. 22 at 10:32 AM
$IRD We just never collapse here. Any news whatsoever and..
0 · Reply
TruthTooPower
TruthTooPower Apr. 20 at 4:30 PM
$IRD!!! NAZ is down!!! Adding on Down Days Looking for my DOUBLE DIGITS!!!
0 · Reply
Shivan007
Shivan007 Apr. 20 at 2:02 PM
$IRD why is it falling? Is there any news?
1 · Reply
Um8a123
Um8a123 Apr. 17 at 11:05 PM
$IRD 6 7 soon!
0 · Reply
jhoffy
jhoffy Apr. 17 at 8:40 PM
$IRD WHat a beautiful chart. This looks ready to get through 6. I think it's a double from here by years end
0 · Reply
dick_dasterdly
dick_dasterdly Apr. 17 at 4:53 PM
$IRD I've got the patience for this. If I were unfortunate to lose any of my senses..my eyes would be the one I wouldn't want to be affected.
0 · Reply
signaljumper
signaljumper Apr. 17 at 12:27 PM
$IRD lets Bring IT above 6 bucks today
0 · Reply
signaljumper
signaljumper Apr. 16 at 1:11 PM
$IRD 1 week in a Trading range 5.80 Close above and WE will See the next Leg Up.
0 · Reply
TruthTooPower
TruthTooPower Apr. 15 at 7:38 PM
$IRD!!! !!!!!!!D O U B L E-D I G I T S!!!!!!! 🤓🤓🤓🤓🤓🤓🤓🤓🤓🤓🤓🤓
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Apr. 15 at 7:10 PM
$IRD ????????????? lots of questions.
0 · Reply
signaljumper
signaljumper Apr. 15 at 6:33 PM
$IRD 6.35 is the next target. Good consolidarion so far
0 · Reply
dick_dasterdly
dick_dasterdly Apr. 15 at 3:04 PM
$IRD Patience humanoids.. patience. And eat , eat , eat shares at these prices.. It'll be here , sooner than they think.
0 · Reply
ifinitis
ifinitis Apr. 14 at 9:20 PM
$IRD Time to go Test $6.60, hold it, and SQease!
0 · Reply
History101
History101 Apr. 11 at 4:43 PM
$IRD 471 watching 4/11/2026
0 · Reply
ifinitis
ifinitis Apr. 10 at 8:22 PM
$IRD If you are trying to Day Trade this stock with Volume, you better know something or you are going to lose money! Seems some newbie is learning this lesson! Adjust your volume to the Float and Daily volume.
0 · Reply